血液透析患者的血浆血管内皮生长因子和血管生成素与促红细胞生成素剂量呈正相关。
Plasma vascular endothelial growth factor and angiogenin are positively related to erythropoietin dose in hemodialysis patients.
机构信息
Nephrology Department, Medical School, University of Thessaly, Larissa, Greece.
出版信息
Adv Med Sci. 2013;58(1):143-9. doi: 10.2478/v10039-012-0071-1.
PURPOSE
Experimental data confirmed that erythropoietin (EPO) administration alters the course of various pathological situations such as heart failure and tumor growth by inducing vascular endothelial growth factor-A (VEGF-A) expression. The effect of EPO dose on plasma VEGF-A level in hemodialysis (HD) patients was evaluated. The effect of EPO dose on plasma angiogenin level in HD patients was also evaluated, since angiogenin is necessary for angiogenesis induced by VEGF-A.
METHODS
Thirty two HD patients (10 diabetics) enrolled into the study. Patients were iron replete and did not suffer from infections, autoimmune diseases or malignancies. Plasma VEGF-A and angiogenin, as well as serum interleukin-6 and tumor necrosis factor-α were measured by means of ELISA.
RESULTS
Weekly EPO dose per kg of dry body weight was positively related to both VEGF-A and angiogenin, whereas no relation was detected among VEGF-A or angiogenin and hemoglobin, inflammation or presence of diabetes mellitus. These relations among EPO dose and VEGF-A or angiogenin remained after adjustment for hemoglobin concentration or inflammation or presence of diabetes mellitus.
CONCLUSIONS
EPO dose may affect plasma VEGF-A and angiogenin concentrations in HD patients.
目的
实验数据证实，促红细胞生成素（EPO）通过诱导血管内皮生长因子-A（VEGF-A）的表达，改变心力衰竭和肿瘤生长等各种病理情况的进程。评估 EPO 剂量对血液透析（HD）患者血浆 VEGF-A 水平的影响。还评估了 EPO 剂量对 HD 患者血浆血管生成素水平的影响，因为血管生成素是 VEGF-A 诱导的血管生成所必需的。
方法
32 名血液透析患者（10 名糖尿病患者）纳入研究。患者铁充足，无感染、自身免疫性疾病或恶性肿瘤。通过 ELISA 法测定血浆 VEGF-A 和血管生成素，以及血清白细胞介素-6 和肿瘤坏死因子-α。
结果
每周每公斤干体重的 EPO 剂量与 VEGF-A 和血管生成素呈正相关，而 VEGF-A 或血管生成素与血红蛋白、炎症或糖尿病之间没有关系。在调整血红蛋白浓度、炎症或糖尿病存在后，EPO 剂量与 VEGF-A 或血管生成素之间的这些关系仍然存在。
结论
EPO 剂量可能影响血液透析患者的血浆 VEGF-A 和血管生成素浓度。
Zotero 插件